EP2866830A4 - Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation - Google Patents

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Info

Publication number
EP2866830A4
EP2866830A4 EP12880044.8A EP12880044A EP2866830A4 EP 2866830 A4 EP2866830 A4 EP 2866830A4 EP 12880044 A EP12880044 A EP 12880044A EP 2866830 A4 EP2866830 A4 EP 2866830A4
Authority
EP
European Patent Office
Prior art keywords
cxcl11
cxcl13
cxcl9
cxcr5
cxcl10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12880044.8A
Other languages
German (de)
French (fr)
Other versions
EP2866830A1 (en
Inventor
James W Lillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JYANT TECHNOLOGIES
Original Assignee
JYANT TECHNOLOGIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JYANT TECHNOLOGIES filed Critical JYANT TECHNOLOGIES
Publication of EP2866830A1 publication Critical patent/EP2866830A1/en
Publication of EP2866830A4 publication Critical patent/EP2866830A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
EP12880044.8A 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation Withdrawn EP2866830A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Publications (2)

Publication Number Publication Date
EP2866830A1 EP2866830A1 (en) 2015-05-06
EP2866830A4 true EP2866830A4 (en) 2015-12-09

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12880044.8A Withdrawn EP2866830A4 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Country Status (5)

Country Link
EP (1) EP2866830A4 (en)
JP (1) JP2015524793A (en)
CN (2) CN104870013A (en)
HK (1) HK1212628A1 (en)
WO (1) WO2014003742A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154795A1 (en) * 2014-04-08 2015-10-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Combination therapy for the treatment of autoimmune diseases
CN105039319A (en) * 2015-06-22 2015-11-11 浙江理工大学 Biomarker for forecasting new auxiliary chemotherapy curative effect of breast cancer and fluorescence quantitative immune PCR kit
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN107236023B (en) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 Antigen composition for detecting tuberculosis infection and application thereof
EP3714891B1 (en) 2017-11-24 2024-02-14 Seoul National University R&DB Foundation Anti-inflammatory composition comprising graphene nano-structure
CN110511912B (en) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 Functional modulation of immune cells
CN109777784B (en) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 Construction method and application of chimeric antigen receptor vector for enhancing migration to tumor part
JP2022544169A (en) 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド Treatment and prevention of cardiovascular disease
EP3960861A1 (en) * 2020-08-31 2022-03-02 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers that target cxcl9
CN114432502B (en) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） Hydrogel loaded with OP3-4 polypeptide and anti-CXCL 9 antibody, and preparation method and application thereof
TW202345871A (en) * 2022-03-30 2023-12-01 美商旗艦先鋒創新公司 Cxcl-modulating compositions and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360689T1 (en) * 1996-09-10 2007-05-15 Kocher Theodor Inst CXCR3 CHEMOKINE RECEPTOR, ANTIBODIES, NUCLIC ACIDS AND METHOD OF USE THEREOF
LT2195023T (en) * 2007-08-29 2018-06-25 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2611832B1 (en) * 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 *
FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638 *
FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S *
JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240 *
RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783 *
See also references of WO2014003742A1 *

Also Published As

Publication number Publication date
CN112807427A (en) 2021-05-18
WO2014003742A1 (en) 2014-01-03
JP2015524793A (en) 2015-08-27
HK1212628A1 (en) 2016-06-17
CN104870013A (en) 2015-08-26
EP2866830A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
HRP20171474T1 (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
HK1212628A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2911669A4 (en) Synergistic combination of immunologic inhibitors for the treatment of cancer
IL269166A (en) Methods and compositions for treating inflammation
EP2920149A4 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP2675469A4 (en) Compositions, devices and methods of use thereof for the treatment of cancers
EP2895609A4 (en) Methods and compostions for the specific inhibition of myc by double-stranded rna
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1199705A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1199015A1 (en) Treatment of inflammation
EP2858648A4 (en) Methods and compositions for the inhibition of pin1
EP2828241A4 (en) Compositions and methods for inhibition of cathepsins
EP2897689A4 (en) Systems, compositions and methods for the treatment of alopecia
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2688901A4 (en) INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
EP2939668A4 (en) Pdk4 inhibitor and use thereof
EP2858634A4 (en) Compounds for treating inflammation and pain
EP2861228A4 (en) Compounds for treating inflammation and pain
GB201100651D0 (en) Treatment of inflammation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20151023BHEP

Ipc: A61P 29/00 20060101ALI20151023BHEP

Ipc: A61K 39/395 20060101AFI20151023BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151106

17Q First examination report despatched

Effective date: 20170406

18D Application deemed to be withdrawn

Effective date: 20170817

18RA Request filed for re-establishment of rights before grant

Effective date: 20180626

D18D Application deemed to be withdrawn (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20200113